Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition

• DOI: 10.1007/s00262-023-03541-0
• Publication Date: 2023-10-04T17:02:08Z
• Authors: Mick J. M. van Eijs; Rik J. Verheijden; Stefanie A. van d...; Stefan Nierkens; Anne S. R. van Li...; Karijn P. M. Suij...; Femke van Wijk; ; Linde Meyaard; Jürgen H. E. Kuball; Bas Oldenburg; Jeanette H. W. Le...
• Keywords: Immune checkpoint

Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of advanced malignancies, but come with a diverse spectrum immune-related adverse events (irAEs). Mechanistic studies can aid transition from expert-opinion to evidence-based irAE strategies. We aimed longitudinally characterize peripheral blood T and B cell dynamics in ICI-treated patients by multicolor flow cytometry serum multiplex immunoassay at baseline, ± 3 weeks 6 or upon clinically relevant irAEs. analyzed samples 44 (24 anti-PD-1 monotherapy, 20 combined anti-PD-1/anti-CTLA-4; cICI), whom 21 developed irAEs, 10 healthy donors. IrAEs after cICI were characterized significantly enhanced proliferation Th1-associated, mainly (CD4